Overview of the Distribution and Presentation of Patients with Sickle Cell Disorders: A Report from a Tertiary Care Centre in Eastern Part of India
Asian Hematology Research Journal,
Aims: With globalisation, patients with Sickle cell disorders can be found all over the world. Depending on the original genotype, the disease manifestations vary.
This study aimed to assess the distribution and clinical presentation of patients with Sickle homozygous/ heterozygous diseases in the eastern part of India.
Study Design: Retrospective analysis.
Place and duration of study: Department of Hematology at NRS Medical College, Kolkata, between 1st January 2018 to 31st May 2020 (2 years and 4 months).
Methodology: Patients having hemoglobinopathies with any type of Sickle haemoglobin (HbS), such as, Sickle cell anemia/homozygous Sickle cell disorders(SCA); compound heterozygous diseases, like Sickle cell/β thalassemia(HbS/β), Sickle cell/Delta thalassemia (HbS/D), Sickle cell Haemoglobin/E thalassemia(HbS/E); or Sickle cell trait(HbS trait), have been included.
Thorough history was elicited and every patient was clinically examined. Published literature was analysed to assess the differences in disease presentation.
Results: Total 95 patients with a component of HbS were assessed and HbS/β (53.7%) patients comprised the majority, followed by SCA (30.5%). Median age of presentation to our clinic was 17years (range 2-50years). HbS/β and SCA patients had a median age of presentation of 17.5years and 12years, respectively.
Commonest clinical presentation was pain crisis (32,33.7%) - abdominal (11,11.6%) or bone pain (13,13.7%). Other presentations were pallor (26,27.4%), jaundice (12,12.6%) and fever (4,4.2%). Most patients had more than one complaint. Occasional patients required hospital admission for pain, fever or convulsions. HbS trait (5,5.3%) was diagnosed incidentally.
Most patients who attended our center hailed from the nearby district of North 24 Parganas (26,27.4%), and fewer patients came from distant districts and neighbouring states.
Patients were treated with Hydroxyurea, with/without blood transfusions or chelation.
Conclusion: Most studies conducted in India have highlighted the prevalence of Sickle cell disorders among specific endemic populations, unlike in our analysis.
HbS/β was more common than SCA, and, median age of disease presentation was later than that in published literature. There is a variation in the severity of disease manifestation in our cohort. Commonest painful crisis was bone pain, followed by abdominal pain. Stroke, a common manifestation of SCA in other countries, was rare in our cohort.
- Sickle cell disorders
- clinical presentation
How to Cite
Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017; 376:1561-1573.
Colah RB, Mukherjee MB, Martin S, Ghosh K. Sickle cell disease in tribal populations in India. Indian J Med Res. 2015;141(5): 509-515.
Hockham C, Bhatt S, Colah R, Mukherjee MB, Penman BS, Gupta S, Piel FB. The spatial epidemiology of sickle-cell anaemia in India. Scientific Reports. 2018;8(1): 17685.
Chakraborty A, Basak J, Majumdar D, Mukhopadhyay S, Chakraborty S, Mukhopadhyay A. Prevalence of Sickle Cell Anemia In Eastern India. Blood. 2010;116;(21):4822.
Mukherjee MB, Nadkarni AH, Gorakshakar AC, Ghosh K, Mohanty D, Colah RB. Clinical, hematologic and molecular variability of sickle cell-β thalassemia in western India. Indian J Hum Genet. 2010 ;16(3):154-8.
Gorakshakar AC. Epidemiology of Sickle Hemoglobin in India. Proceeding of National Symposium on Tribal Health. Abstract Book. 2006:103- 108.
Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. Scientific World Journal. 2013:193252.
Siddiqi AE, Jordan LB, Parker CS. Sickle cell disease--the American saga. Ethn Dis. 2013;23(2):245-248.
Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4Suppl):S512-S521.
Yanni E, Grosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr. 2009;154(4):541-545. doi: 10.1016/j.jpeds.2008.09.052.
Brozović M, Anionwu E. Sickle cell disease in Britain. J Clin Pathol. 1984;37(12):1321-1326. DOI:10.1136/jcp.37.12.1321.
Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med. 2011;31(3):289-293.
Hazzazi AA, Ageeli MH, Alfaqih AM, Jaafari AA, Malhan HM, Bakkar MM. Epidemiology and characteristics of sickle cell patients admitted to hospitals in Jazan region, Saudi Arabia. Journ of Applied Hemat. 2020;11(1):10-14.
Wastnedge E, Waters D, Patel S, et al. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health. 2018;8(2):021103. DOI:10.7189/jogh.08.021103.
Italia K, Jain D, Gattani S, et al. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009;42(1):25-31.
Mishra S, Chhabra G. Sickle cell anemia: An update on diagnosis, management and prevention strategies. Indian Journ of Comm and Family Med. 2018;4(2):67-71. DOI: 10.4103/2395-2113.251444.
Abstract View: 30 times
PDF Download: 33 times